gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nafamostat

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Covistat

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 06, 2020

            Details:

            Nafamostat works by affecting the body's own enzymes—not the virus, which is capable of mutating to evade treatments. Nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Zika-HX antigen

            Therapeutic Area: Infections and Infectious Diseases Product Name: Zika vaccine

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: CPI

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 13, 2020

            Details:

            Excivion has partnered with CPI to draw upon the company’s extensive experience in the optimisation and scale-up of biologics manufacturing processes to optimise the manufacture of their novel Zika vaccine antigen candidate, Zika-HX.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fentanyl

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ethypharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 04, 2020

            Details:

            The collaboration is intended to accelerate the manufacture and batch release of fentanyl injection; one of the critical medicines needed for the treatment of COVID-19 patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Live modified horsepox virus vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Tonix Pharmaceuticals Holding Corp

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2020

            Details:

            Under the agreement, Fujifilm Diosynth Biotechnologies will develop a manufacturing process, manufacture, and stock a supply of TNX-1800 at FDB’s College Station, Texas site for Tonix’s clinical development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Covigenix

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Entos Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2020

            Details:

            Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IPP-201101

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            Investigation of the application of the Ureka peptide technologies within the Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imatinib

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 07, 2020

            Details:

            AI VIVO is seeking pharma and biotech collaboration partners to progress therapeutic candidates that have been identified by the Company as “top-ranked” for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID 19 vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Vaccitech Oncology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 30, 2020

            Details:

            Under the new agreement, AstraZeneca will work with global partners on the international distribution COVID-19 vaccine, to make it available and accessible for low and medium income countries.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): COVID-19-adenovirus vector-based vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            Valo Tx's PeptiCRAd technology to coat non-replicating adenovirus expressing COVID-19 Spike, with HLA-matched peptides tailored to boost immune responses of CD8 + T-cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antibodies

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: FairJourney Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership April 16, 2020

            Details:

            The combination will enable the newly created partnership to isolate highly specific, neutralizing SARS-CoV-2 antibodies displaying high affinity and preferential biophysical characteristics.

            PharmaCompass